All the funding deals in the cell therapy market
Last updated: 13 July 2026
Download our beautiful pitch about the cell therapy market
In our cell therapy market deck, you will find everything you need to understand the market
The cell therapy market is attracting strong investor interest across cancer, autoimmune diseases, neurological disorders, regenerative medicine, and other major healthcare needs.
We conducted deep research and collected 77 cell therapy funding deals announced between 2024 and the second quarter of 2026.
We refresh this page very often to add newly announced cell therapy funding deals and improve existing information.
And if you want to better understand this new industry, you should get our beautiful slides covering the cell therapy market.
Insights
- The 77 cell therapy funding deals in this list represent approximately $6.7 billion in disclosed financing between 2024 and Q2 2026.
- The cell therapy market raised about $3.6 billion across the deals identified in 2024, more than half of the total capital in this analysis.
- Large public offerings had a major impact on cell therapy funding. Autolus, Kyverna, ArsenalBio, Artiva, Nkarta, and Allogene each raised at least $200 million.
- CAR-T remained the most common investment theme in the cell therapy market, but investors increasingly backed autoimmune disease programs alongside traditional cancer treatments.
- In vivo CAR-T became a stronger cell therapy funding category during 2025 and 2026, with financing for Umoja Biopharma, Stylus Medicine, Azalea Therapeutics, CREATE Medicines, and Vivacta Bio.
- Regenerative cell therapy also attracted significant capital. Neurona Therapeutics, Aspen Neuroscience, MEDIPOST, Aspect Biosystems, and Orca Bio each announced rounds above $100 million.
- Several cell therapy companies raised money more than once during the period. Neurona Therapeutics, Century Therapeutics, Allogene Therapeutics, Artiva Biotherapeutics, BrainStorm Cell Therapeutics, and Tr1X returned to investors.
- The cell therapy market remained global, with funded companies based across North America, Europe, and Asia, including India, China, Japan, South Korea, Finland, Germany, Sweden, and the United Kingdom.
This chart, featured in our cell therapy market deck, shows annual VC investment in cell therapy startups
Summary table of the funding deals for the cell therapy market since 2024
We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.
We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.
We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.
We focused exclusively on pure players, defined as companies with at least 70–80% of their business directly tied to the cell therapy market.
Our analysis has been done at a global level with a minimum funding threshold of $300k.
You can also read our detailed analysis to understand how funding activity in the cell therapy market has evolved recently.
If you want a longer-term view, we also have a study of how funding activity in the cell therapy market has changed over the years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the cell therapy market.
| Name | What they do | Amount in $ | Quarter | Source(s) |
|---|---|---|---|---|
| Syntax Bio | Develops programmed stem-cell therapies that could replace insulin-producing cells in people with diabetes | $14.4M | Q2 2026 | BioSpace |
| Immuneel Therapeutics | Develops and provides CAR-T cell therapies for patients in India and other markets | $12.0M | Q2 2026 | YourStory |
| BioCardia | Develops cell-based and cell-derived treatments for cardiovascular and pulmonary diseases | $4.4M | Q2 2026 | BioCardia |
| iRegene Therapeutics | Develops iPSC-derived regenerative cell therapies for Parkinson’s disease and other conditions | $29.6M | Q2 2026 | VCBeat Health |
| Waypoint Bio | Uses spatial biology and AI to design CAR-T therapies for solid tumors | $20.0M | Q2 2026 | BioSpace |
| BrainStorm Cell Therapeutics | Develops adult stem-cell therapies for neurodegenerative diseases | $0.4M | Q2 2026 | PR Newswire |
| CREATE Medicines | Develops in vivo immune-cell therapies for autoimmune diseases and cancer | $122.0M | Q2 2026 | PR Newswire |
| Artiva Biotherapeutics | Develops ready-made NK-cell therapies for autoimmune diseases and cancer | $300.0M | Q2 2026 | Artiva Biotherapeutics |
| Vivacta Bio | Develops in vivo CAR-T therapies for cancer and autoimmune diseases | $50.0M | Q2 2026 | PR Newswire |
| Allogene Therapeutics | Develops ready-made CAR-T therapies for cancer and autoimmune diseases | $200.4M | Q2 2026 | Allogene Therapeutics |
| Lyell Immunopharma | Develops next-generation CAR-T therapies for cancer | $50.0M | Q1 2026 | Lyell Immunopharma |
| BrainStorm Cell Therapeutics | Develops adult stem-cell therapies for neurodegenerative diseases | $2.0M | Q1 2026 | PR Newswire |
| BioRestorative Therapies | Develops stem-cell therapies for spinal conditions, metabolic diseases, and other disorders | $5.0M | Q1 2026 | BioRestorative Therapies |
| Regend Therapeutics | Develops stem-cell and progenitor-cell therapies that help repair damaged organs | $50.3M | Q1 2026 | Regend Therapeutics |
| Ernexa Therapeutics | Develops cell therapies for advanced cancer and autoimmune diseases | $10.5M | Q1 2026 | Ernexa Therapeutics |
| OriCell Therapeutics | Develops CAR-T therapies for solid tumors and blood cancers | $70.0M | Q1 2026 | PR Newswire |
| Cytotheryx | Develops cell-based treatments for liver disease | $60.0M | Q1 2026 | Cytotheryx |
| MEDIPOST | Develops umbilical cord blood-derived stem-cell therapies for degenerative diseases | $140.0M | Q1 2026 | Business Wire |
| Orca Bio | Develops precise donor-cell therapies for blood cancers and other serious blood diseases | $250.0M | Q1 2026 | Orca Bio |
| Century Therapeutics | Develops iPSC-derived cell therapies for autoimmune diseases and cancer | $135.0M | Q1 2026 | Century Therapeutics |
| Pan Cancer T | Develops TCR-T cell therapies for solid tumors, including breast cancer | $5.25M | Q4 2025 | Pan Cancer T |
| Link Cell Therapies | Develops next-generation CAR-T therapies for solid tumors and blood cancers | $60.0M | Q4 2025 | Link Cell Therapies |
| Aspen Neuroscience | Develops personalized stem-cell therapies for Parkinson’s disease and other neurological conditions | $115.0M | Q4 2025 | Aspen Neuroscience |
| T-CURX | Develops non-viral CAR-T therapies for leukemia and solid tumors | $20.0M | Q4 2025 | T-CURX |
| Vyriad | Develops targeted genetic medicines, including an in vivo CAR-T treatment | $25.0M | Q4 2025 | Vyriad |
| Tr1X | Develops engineered regulatory T-cell therapies for autoimmune and inflammatory diseases | $50.0M | Q4 2025 | Tr1X |
| Captain T Cell | Develops next-generation TCR-T cell therapies for solid tumors | $21.7M | Q4 2025 | Captain T Cell |
| DeliNova Therapeutics | Develops in vivo CAR-T therapies using lentiviral delivery technology | $8.3M | Q4 2025 | The Pharma Letter |
| Azalea Therapeutics | Develops technology that engineers cells and genes directly inside patients | $82.0M | Q4 2025 | GlobeNewswire |
| A-SEEDS | Develops non-viral, gene-modified CAR-T therapies using piggyBac technology | $15.0M | Q3 2025 | A-SEEDS |
| NK CellTech | Develops NK-cell therapies for cancer, autoimmune diseases, and degenerative conditions | $14.0M | Q3 2025 | NK CellTech |
| Dispatch Bio | Tags solid-tumor cells so engineered immune cells can find and destroy them | $216.0M | Q3 2025 | Dispatch Bio |
| Lyell Immunopharma | Develops next-generation CAR-T therapies for cancer | $50.0M | Q3 2025 | Lyell Immunopharma |
| Gameto | Develops stem-cell-based treatments for fertility and reproductive health | $44.0M | Q3 2025 | PR Newswire |
| Anocca | Develops gene-edited TCR-T therapies for solid tumors, including pancreatic cancer | $46.0M | Q3 2025 | Business Wire |
| Wugen | Develops ready-made CAR-T therapies for leukemia and other blood cancers | $115.0M | Q3 2025 | Wugen |
| MagicRNA Biotech | Develops mRNA-based in vivo CAR-T therapies for autoimmune diseases and other conditions | $14.0M | Q3 2025 | PE Daily |
| Innovacell | Develops muscle-cell therapies for fecal and urinary incontinence | $48.0M | Q3 2025 | Fierce Biotech |
| Rui Therapeutics | Develops engineered CAR-NK and CAR-T therapies for immune and inflammatory diseases | $28.0M | Q3 2025 | OncoDaily |
| iRegene Therapeutics | Develops iPSC-derived cell therapies for Parkinson’s disease and retinal degeneration | $40.0M | Q3 2025 | PR Newswire |
| Neurona Therapeutics | Develops regenerative neural cell therapies for epilepsy and other neurological disorders | $102.0M | Q2 2025 | Neurona Therapeutics |
| Stylus Medicine | Develops genetic medicines that can create CAR-T cells inside patients | $85.0M | Q2 2025 | Business Wire |
| Somite AI | Uses artificial intelligence to develop human cell therapies and cell-generation models | $47.0M | Q2 2025 | Chan Zuckerberg Initiative |
| Umoja Biopharma | Develops treatments that create CAR-T cells directly inside patients | $100.0M | Q1 2025 | Umoja Biopharma |
| Optieum Biotechnologies | Develops next-generation CAR-T therapies for brain tumors and other cancers | $8.6M | Q1 2025 | Optieum Biotechnologies |
| ONGENO | Develops a bone-marrow-derived stem-cell therapy for multiple sclerosis | $3.6M | Q1 2025 | AIN |
| StemSight | Develops stem-cell therapies that aim to restore vision | $2.4M | Q1 2025 | StemSight |
| Inceptor Bio | Develops next-generation CAR-T therapies for kidney cancer and other solid tumors | $21.0M | Q1 2025 | Inceptor Bio |
| Garuda Therapeutics | Develops ready-made blood stem-cell therapies for severe blood disorders | $50.0M | Q1 2025 | BioSpace |
| HemaCell Therapeutics | Develops iPSC-derived platelets and other blood-cell therapies | $2.8M | Q1 2025 | VCBeat Health |
| A2 Biotherapeutics | Develops logic-gated CAR-T therapies that target cancer while protecting healthy cells | $80.0M | Q1 2025 | Business Wire |
| Aspect Biosystems | Develops bioprinted tissue therapies for endocrine and metabolic diseases | $115.0M | Q1 2025 | Business Wire |
| Lineage Cell Therapeutics | Develops ready-made cell replacement therapies for retinal, spinal, auditory, and metabolic conditions | $30.0M | Q4 2024 | Business Wire |
| March Biosciences | Develops CAR-T therapy for T-cell lymphoma and other difficult cancers | $28.4M | Q4 2024 | BioSpace |
| AvenCell Therapeutics | Develops switchable CAR-T therapies for blood cancers and autoimmune diseases | $112.0M | Q4 2024 | AvenCell Therapeutics |
| Be Biopharma | Develops engineered B-cell medicines for hemophilia and other serious diseases | $82.0M | Q4 2024 | Be Biopharma |
| Resolution Therapeutics | Develops macrophage cell therapies for liver disease and inflammatory conditions | $83.3M | Q4 2024 | PR Newswire, Precision Medicine Online |
| GC Therapeutics | Uses transcription factors to produce iPSC-derived cell therapies | $65.0M | Q3 2024 | GC Therapeutics |
| ArsenalBio | Develops programmable CAR-T therapies for solid tumors | $325.0M | Q3 2024 | ArsenalBio |
| TC BioPharm | Develops gamma-delta T-cell therapies for cancer and other diseases | $2.0M | Q3 2024 | PR Newswire |
| Outpace Bio | Uses artificial intelligence to design programmed T-cell therapies for solid tumors | $144.0M | Q3 2024 | Outpace Bio |
| Artiva Biotherapeutics | Develops ready-made NK-cell therapies for autoimmune diseases and cancer | $167.0M | Q3 2024 | Artiva Biotherapeutics |
| Cartesian Therapeutics | Develops mRNA CAR-T therapies for autoimmune diseases | $130.0M | Q3 2024 | Selecta Biosciences |
| BrainStorm Cell Therapeutics | Develops adult stem-cell therapies for neurodegenerative diseases | $4.0M | Q2 2024 | BrainStorm Cell Therapeutics |
| Allogene Therapeutics | Develops ready-made CAR-T therapies for cancer and autoimmune diseases | $110.0M | Q2 2024 | Nasdaq |
| Century Therapeutics | Develops iPSC-derived NK-cell and T-cell therapies for autoimmune diseases and cancer | $60.0M | Q2 2024 | Century Therapeutics |
| Obsidian Therapeutics | Develops engineered tumor-infiltrating lymphocyte therapies for solid tumors | $160.5M | Q2 2024 | Obsidian Therapeutics |
| Nkarta | Develops engineered NK-cell therapies for cancer and autoimmune diseases | $240.1M | Q1 2024 | FinancialContent |
| Capstan Therapeutics | Develops in vivo CAR-T therapies using targeted RNA delivery | $175.0M | Q1 2024 | Business Wire |
| Kenai Therapeutics | Develops iPSC-derived neuron replacement therapies for Parkinson’s disease | $82.0M | Q1 2024 | Kenai Therapeutics |
| Iovance Biotherapeutics | Develops tumor-infiltrating lymphocyte therapies for cancer | $211.0M | Q1 2024 | BioSpace |
| Sana Biotechnology | Develops engineered and immune-protected cell therapies for serious diseases | $189.75M | Q1 2024 | Yahoo Finance |
| Kyverna Therapeutics | Develops CD19 CAR-T therapies for autoimmune diseases | $319.0M | Q1 2024 | PR Newswire |
| Autolus Therapeutics | Develops programmed T-cell therapies for blood cancers | $550.0M | Q1 2024 | Syncona, BioNTech |
| Neurona Therapeutics | Develops regenerative neural cell therapies for chronic neurological disorders | $120.0M | Q1 2024 | Neurona Therapeutics |
| Adicet Bio | Develops ready-made gamma-delta CAR-T therapies for autoimmune diseases and cancer | $85.2M | Q1 2024 | Business Wire |
| Tr1X | Develops regulatory T-cell therapies for autoimmune and inflammatory diseases | $75.0M | Q1 2024 | PR Newswire |
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Related blog posts
- The latest progress in the cell therapy market
- What is the latest news in the cell therapy market?
- What is the true size of the cell therapy market?
- What are the latest funding developments in the cell therapy market?
- What are the key fundraising trends in the cell therapy market?
- How funding activity has evolved in the cell therapy market
